<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id><journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id><journal-title-group><journal-title>Psychopharmacology</journal-title></journal-title-group><issn pub-type="ppub">0033-3158</issn><issn pub-type="epub">1432-2072</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25288512</article-id><article-id pub-id-type="pmc">4336648</article-id><article-id pub-id-type="publisher-id">3749</article-id><article-id pub-id-type="doi">10.1007/s00213-014-3749-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group></article-categories><title-group><article-title>Cannabis and creativity: highly potent cannabis impairs divergent thinking in regular cannabis users</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Kowal</surname><given-names>Mikael A.</given-names></name><address><phone>+31(0)71 527 38 36</phone><email>m.a.kowal@fsw.leidenuniv.nl</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Hazekamp</surname><given-names>Arno</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Colzato</surname><given-names>Lorenza S.</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>van Steenbergen</surname><given-names>Henk</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>van der Wee</surname><given-names>Nic J. A.</given-names></name><xref ref-type="aff" rid="Aff2"/><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Durieux</surname><given-names>Jeffrey</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Manai</surname><given-names>Meriem</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hommel</surname><given-names>Bernhard</given-names></name><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Cognitive Psychology Unit, Institute of Psychology, Leiden University, PO Box 9555, 2300 RB Leiden, The Netherlands </aff><aff id="Aff2"><label/>Leiden Institute for Brain and Cognition, Leiden, The Netherlands </aff><aff id="Aff3"><label/>Bedrocan BV, Veendam, The Netherlands </aff><aff id="Aff4"><label/>Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>10</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>10</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2015</year></pub-date><volume>232</volume><issue>6</issue><fpage>1123</fpage><lpage>1134</lpage><history><date date-type="received"><day>9</day><month>5</month><year>2014</year></date><date date-type="accepted"><day>15</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2014</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.</license-p></license></permissions><abstract id="Abs1"><sec><title>Rationale</title><p>Cannabis users often claim that cannabis has the potential to enhance their creativity. Research suggests that aspects of creative performance might be improved when intoxicated with cannabis; however, the evidence is not conclusive.</p></sec><sec><title>Objective</title><p>The aim of this study was to investigate the acute effects of cannabis on creativity.</p></sec><sec><title>Methods</title><p>We examined the effects of administering a low (5.5&#x000a0;mg delta-9-tetrahydrocannabinol [THC]) or high (22&#x000a0;mg THC) dose of vaporized cannabis vs. placebo on creativity tasks tapping into divergent (Alternate Uses Task) and convergent (Remote Associates Task) thinking, in a population of regular cannabis users. The study used a randomized, double-blind, between-groups design.</p></sec><sec><title>Results</title><p>Participants in the high-dose group (<italic>n</italic>&#x02009;=&#x02009;18) displayed significantly worse performance on the divergent thinking task, compared to individuals in both the low-dose (<italic>n</italic>&#x02009;=&#x02009;18) and placebo (<italic>n</italic>&#x02009;=&#x02009;18) groups.</p></sec><sec><title>Conclusions</title><p>The findings suggest that cannabis with low potency does not have any impact on creativity, while highly potent cannabis actually <italic>impairs</italic> divergent thinking.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cannabis</kwd><kwd>Creativity</kwd><kwd>Divergent thinking</kwd><kwd>Convergent thinking</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag Berlin Heidelberg 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p>Anecdotal evidence suggests that cannabis intoxication enhances human creativity. In line with that, Steve Jobs, an undeniably creative mind, once stated: &#x0201c;The best way I could describe the effect of the marijuana and hashish is that it would make me relaxed and creative.&#x0201d; Other regular users claim that cannabis induces a state in which they experience unusual and original thoughts (Tart <xref ref-type="bibr" rid="CR52">1970</xref>). In a more recent review, over 50&#x000a0;% of users reported heightened creativity during cannabis intoxication (Green et al. <xref ref-type="bibr" rid="CR24">2003</xref>). This widespread perception of cannabis as a creativity-enhancer makes it important to verify whether cannabis actually induces these supposed effects. Delta-9-tetrahydrocannabinol (THC), the main psychoactive compound present in the <italic>Cannabis sativa</italic> plant, has been found to reduce inhibitory control (McDonald et al. <xref ref-type="bibr" rid="CR37">2003</xref>) and stimulate striatal dopamine (DA) release (Bossong et al. <xref ref-type="bibr" rid="CR9">2009</xref>; Kuepper et al. <xref ref-type="bibr" rid="CR35">2013</xref>). These features of THC intoxication, in turn, are expected to play a role in particular aspects of creative thinking (Akbari Chermahini and Hommel <xref ref-type="bibr" rid="CR2">2010</xref>; Hommel <xref ref-type="bibr" rid="CR31">2012</xref>). On the other hand, THC has been linked to the emergence of psychotic symptoms both due to acute administration (D&#x02019;Souza et al. <xref ref-type="bibr" rid="CR19">2004</xref>), as well as in the long-term (Kuepper et al. <xref ref-type="bibr" rid="CR34">2010</xref>). As a result, the possible beneficial effects of using cannabis, if any, might not outweigh the potential risks associated with its abuse.</p><p>The concept of creativity is not very well defined, and there is no agreement on one particular measure how to assess it. While some authors consider the concept to refer to the product of creative activities, others take it to reflect the personality of the product&#x02019;s creator (for an overview, see Runco <xref ref-type="bibr" rid="CR44">2007</xref>). To circumvent these difficulties, we restricted our analyses to two well-established creative processes and the respective classical assessment methods: divergent and convergent thinking (Guilford <xref ref-type="bibr" rid="CR25">1967</xref>). Divergent thinking takes place when people try to find as many solutions to a loosely defined problem as possible&#x02014;a process often referred to as &#x0201c;brainstorming.&#x0201d; It is often assessed by means of Guilford&#x02019;s (<xref ref-type="bibr" rid="CR25">1967</xref>) Alternate Uses Task (AUT), which requires individuals to generate as many as possible uses for a common household item (such as a pen or book) as they can think of (e.g., reading it, using it as a doorstop, etc.). In contrast, convergent thinking takes place when trying to find the one possible solution to a very well-defined problem. This process is often assessed by means of Mednick&#x02019;s (<xref ref-type="bibr" rid="CR38">1962</xref>) Remote Associates Task (RAT), in which people are presented with three supposedly unrelated concepts (e.g., &#x0201c;time,&#x0201d; &#x0201c;hair,&#x0201d; &#x0201c;stretch&#x0201d;) and are requested to identify the one concept that can be related to all three of them (&#x0201c;long&#x0201d;). Research indicates that performance in AUT and RAT is not (strongly) correlated (Akbari Chermahini and Hommel <xref ref-type="bibr" rid="CR2">2010</xref>; Akbari Chermahini et al. <xref ref-type="bibr" rid="CR3">2012</xref>). Moreover, there is evidence that the two types of creative thinking are differently related to subcortical DA levels: While divergent thinking performance relates to markers of DA levels in the form of an inverted U-shape, convergent thinking performance displays a linear, negative correlation with DA markers (Akbari Chermahini and Hommel <xref ref-type="bibr" rid="CR2">2010</xref>). In addition, this dissociation of human creativity seems to correspond to the dual pathway to creativity model (De Dreu et al. <xref ref-type="bibr" rid="CR17">2008</xref>; Nijstad et al. <xref ref-type="bibr" rid="CR40">2010</xref>) suggesting that creative performance emerges from the balance between cognitive flexibility and cognitive persistence&#x02014;two dissociable cognitive control functions (De Dreu et al. <xref ref-type="bibr" rid="CR18">2012</xref>).</p><p>With regard to the neural effects of THC, the link between creative thinking and DA appears to be particularly interesting. Administration of THC has been shown to indirectly induce DA release in the striatum (Bossong et al. <xref ref-type="bibr" rid="CR9">2009</xref>; Kuepper et al. <xref ref-type="bibr" rid="CR35">2013</xref>), and there is evidence that its chronic application can lead to dopaminergic hypoactivity in the long-term, especially if the onset of cannabis use is at a young age (Hoffman et al. <xref ref-type="bibr" rid="CR30">2003</xref>; Urban et al. <xref ref-type="bibr" rid="CR56">2012</xref>; Bloomfield et al. <xref ref-type="bibr" rid="CR7">2014</xref>). As divergent thinking performance is expected to be optimal with medium subcortical DA levels (Akbari Chermahini and Hommel <xref ref-type="bibr" rid="CR2">2010</xref>), one may suspect that THC can have a beneficial effect on this creative process, particularly in individuals with low dopaminergic functioning. This assumption is further supported by the fact that the reduction in inhibitory control, as observed in response to stimulation by pure THC (McDonald et al. <xref ref-type="bibr" rid="CR37">2003</xref>) and cannabis (Ramaekers et al. <xref ref-type="bibr" rid="CR41">2006</xref>; Ramaekers et al. <xref ref-type="bibr" rid="CR42">2009</xref>), has been related to dopaminergic functioning as well (Mink <xref ref-type="bibr" rid="CR39">1996</xref>). Reduced inhibitory control can be considered to reflect a cognitive control state with weak top-down guidance. Such a state should affect convergent and divergent thinking differently (Hommel <xref ref-type="bibr" rid="CR31">2012</xref>). As pointed out by Bogacz (<xref ref-type="bibr" rid="CR8">2007</xref>), human decision-making and the retrieval of possible alternatives can be considered a process that emerges from the interaction of top-down guidance and low-level competition between alternatives. If so, convergent thinking, with its many top-down constraints targeting one single solution, would seem to require a control state that provides strong top-down guidance and strong local competition. In contrast, divergent thinking, with its loosely defined problem and its many solutions, seems to require a control state that provides weak top-down guidance and only little local competition (Hommel <xref ref-type="bibr" rid="CR31">2012</xref>). To the degree that THC indeed induces a control state with weak top-down guidance and local competition, it might thus be expected to improve divergent thinking, interfere with convergent thinking, or both (Hommel <xref ref-type="bibr" rid="CR31">2012</xref>; Colzato et al. <xref ref-type="bibr" rid="CR11">2012</xref>).</p><p>Unfortunately, the available research on the link between cannabis and creativity allows only for partial verification of these expectations. With respect to divergent thinking, one study showed that subjects intoxicated with joints (cannabis cigarettes) containing a low dose of THC (3&#x000a0;mg in total) displayed significantly enhanced performance on two divergent production tasks, compared to a group that received a higher THC dose (6&#x000a0;mg in total; Weckowicz et al. <xref ref-type="bibr" rid="CR57">1975</xref>). Curran et al. (<xref ref-type="bibr" rid="CR16">2002</xref>) showed that, as compared to placebo, oral THC (7.5 and 15&#x000a0;mg) dose-dependently improved verbal fluency&#x02014;an important aspect of divergent thinking (Guilford <xref ref-type="bibr" rid="CR25">1967</xref>), at least as assessed by the AUT. Improved verbal fluency performance was also found in a naturalistic study that showed beneficial effect of smoked cannabis (10&#x000a0;% THC on average) on divergent thinking to be restricted to users low in trait creativity (i.e., individuals that obtained a low score on a self-assessment questionnaire about achievements in different creative domains; Schafer et al. <xref ref-type="bibr" rid="CR47">2012</xref>). In addition to fluency, cannabis administration (joints containing 19&#x000a0;mg of THC) has also been shown to increase the number of original responses on a test of associative processes, in comparison to placebo (Block et al. <xref ref-type="bibr" rid="CR6">1992</xref>). In contrast, Tinklenberg et al. (<xref ref-type="bibr" rid="CR54">1978</xref>) did not observe any improvement in performance during the Torrance Tests of Creative Thinking (TTCT; Torrance <xref ref-type="bibr" rid="CR55">1966</xref>), which is often assumed to tap into divergent thinking, after oral consumption of THC (a biscuit containing 0.3&#x000a0;mg/kg body weight of THC). Another study found decreased TTCT scores for fluency, flexibility, and elaboration after smoking a cannabis joint (containing 10&#x000a0;mg of THC) in regular cannabis users but not in first-time users (Bourassa and Vaugeois <xref ref-type="bibr" rid="CR10">2001</xref>). In summary, the methodological differences between the various studies aside, many but not all findings suggest that THC may induce a cognitive control state with weak top-down guidance, thus efficiently decreasing the competition between cognitive representations and enhancing divergent thinking (Hommel <xref ref-type="bibr" rid="CR31">2012</xref>; Colzato et al. <xref ref-type="bibr" rid="CR11">2012</xref>).</p><p>For convergent thinking, the evidence is even more limited. Weckowicz et al. (<xref ref-type="bibr" rid="CR57">1975</xref>) observed a trend toward less efficient convergent thinking task after smoking joints containing a low dose of THC (3&#x000a0;mg in total) or a higher dose (6&#x000a0;mg in total), in comparison to both a placebo and a pure control group. However, the same study also found impaired convergent thinking but only for the high-dose condition. The most recent investigation found potentially detrimental effects of smoking cannabis (10&#x000a0;% THC on average) on RAT performance in a group of cannabis users assumed to be high in trait creativity (Schafer et al. <xref ref-type="bibr" rid="CR47">2012</xref>). Although the naturalistic approach of this study makes it difficult to account for specific dose-related differences, the results of the research of both Schafer et al. (<xref ref-type="bibr" rid="CR47">2012</xref>) and Weckowicz et al. (<xref ref-type="bibr" rid="CR57">1975</xref>) suggest that THC can disrupt the process of searching and converging on a single solution to a problem.</p><p>A number of the observed inconsistencies between studies might be due to differences with respect to THC dosage and method of administration, which, in turn, affects the bioavailability and the onset of action of the compound (Hazekamp et al. <xref ref-type="bibr" rid="CR28">2006</xref>). Moreover, an individual&#x02019;s history of cannabis use needs to be identified before cognitive changes in response to THC can be predicted. Administration of joints (containing up to 39&#x000a0;mg of THC) to regular cannabis users has been found to produce no accuracy impairments on a test battery assessing several cognitive functions (Hart et al. <xref ref-type="bibr" rid="CR26">2001</xref>) and, more specifically, on tasks related to episodic and working memory (Hart et al. <xref ref-type="bibr" rid="CR27">2010</xref>). Furthermore, after smoking a cannabis joint (containing 500&#x000a0;&#x003bc;g/kg body weight THC), chronic users did not display any behavioral deficiencies on tasks assessing tracking performance and divided attention (Ramaekers et al. <xref ref-type="bibr" rid="CR42">2009</xref>) or changes in an event-related potential (ERP) reflecting early attentional processes (Theunissen et al. <xref ref-type="bibr" rid="CR53">2012</xref>), compared to infrequent users. In addition, regular cannabis users were shown to display reduced sensitivity to the psychotomimetic effects of THC (administered as an intravenous dose up to 5&#x000a0;mg; D&#x02019;Souza et al. <xref ref-type="bibr" rid="CR20">2008</xref>). In contrast, inhibitory control has been found to be similarly impaired among both occasional and chronic users when intoxicated with cannabis (Ramaekers et al. <xref ref-type="bibr" rid="CR42">2009</xref>).</p><p>Accordingly, since research points to reduced cannabinoid receptor type 1 (CB<sub>1</sub>) density in the brains of regular cannabis users (Hirvonen et al. <xref ref-type="bibr" rid="CR29">2012</xref>), one may suspect that the tolerance of chronic users to some of the detrimental effects of THC is, to some extent, related to their dopaminergic functioning. Specifically, due to the concentration of CB<sub>1</sub> receptors at gamma-aminobutyric acid (GABA) and glutamate neurons, CB<sub>1</sub> receptor downregulation can influence the activity of these neurotransmitters (Hoffman et al. <xref ref-type="bibr" rid="CR30">2003</xref>). Because DA neurons are frequently co-localized with GABAergic and glutamatergic terminals, the dopaminergic deficiencies observed in chronic cannabis users may be explained by lasting, maladaptive modulation of DA by GABA and glutamate (Fattore et al. <xref ref-type="bibr" rid="CR21">2010</xref>; Fern&#x000e1;ndez-Ruiz et al. <xref ref-type="bibr" rid="CR22">2010</xref>). If so, keeping in mind the inverted U-shape relationship between subcortical DA levels and divergent thinking performance (Akbari Chermahini and Hommel <xref ref-type="bibr" rid="CR2">2010</xref>) and the effect of THC on striatal DA release (Bossong et al. <xref ref-type="bibr" rid="CR9">2009</xref>; Kuepper et al. <xref ref-type="bibr" rid="CR35">2013</xref>), it may be expected that individuals with a relatively low level of dopaminergic functioning, such as regular cannabis users, are more likely to demonstrate enhanced performance on a divergent thinking task, provided that the THC dose is not excessively high. In contrast, in a population without long-term dopaminergic imbalances, such as healthy drug-na&#x000ef;ve individuals, even a reasonably low dose of THC could stimulate DA production to the level that it exceeds the threshold for optimal performance. In the case of convergent thinking performance, which is best with low subcortical DA levels (Akbari Chermahini and Hommel <xref ref-type="bibr" rid="CR2">2010</xref>), it may be predicted that it will deteriorate in response to THC, irrespective of the dose and cannabis use history of the individual.</p><p>In order to examine these possibilities, we investigated the effect of two different doses of vaporized cannabis (containing 5.5 or 22&#x000a0;mg THC; see &#x0201c;Study drugs&#x0201d; section) and placebo on convergent and divergent thinking in a sample of chronic cannabis users, using a between-groups design. On the basis of the assumption that a low dose of cannabis can remove potential impairments caused by regular use (Weckowicz et al. <xref ref-type="bibr" rid="CR57">1975</xref>; Kelleher et al. <xref ref-type="bibr" rid="CR33">2004</xref>), we expected that participants intoxicated with a low dose of cannabis should display higher scores on a divergent thinking task, compared to placebo. Conversely, we predicted impairment of performance in the high-dose condition, in contrast to the low-dose and placebo conditions. In the case of convergent thinking, we expected that both doses of cannabis should impair this process, compared to placebo. In addition, since divergent thinking performance has been found to be related to an individual&#x02019;s mood (Zenasni and Lubart <xref ref-type="bibr" rid="CR58">2011</xref>), we assessed perceived mood as a possible modulating factor.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><p>The current study was part of a larger study which involved additional tasks and measurements.</p><sec id="Sec3"><title>Participants</title><p>Power analysis was performed to assess the approximate number of subjects required for detecting medium (<italic>d</italic>&#x02009;=&#x02009;0.5) or large effect sizes (<italic>d</italic>&#x02009;=&#x02009;0.8). Consequently, with an expected sample size of 60, three conditions, and a set alpha of 0.05, the power to detect main effects with a medium or large effect size for a between-group ANOVA is 0.679 and 0.979, respectively. Calculations were made using the analysis program fpower (Friendly <xref ref-type="bibr" rid="CR23">2014</xref>).</p><p>Fifty-nine healthy regular cannabis users (52 males and 7 females) participated in the study in exchange for a small financial compensation. Subjects were recruited through advertisements on the internet, on community bulletin boards, and in coffee shops (outlets in which Dutch law permits the sale of small quantities of cannabis to consumers) and by word of mouth. Detailed demographic and substance use information is presented in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Written informed consent was obtained from all participants, after a complete explanation of the nature of the study. The study was approved by the Medical Ethics Committee of the Leiden University Medical Center.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Demographic and substance use data for each experimental group</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Placebo</th><th>5.5&#x000a0;mg THC</th><th>22&#x000a0;mg THC</th><th>Significance level</th></tr></thead><tbody><tr><td>
<italic>N</italic> (male/female)</td><td>18 (18:0)</td><td>18 (17:1)</td><td>18 (13:5)</td><td>
<italic>p</italic>&#x02009;=&#x02009;0.019</td></tr><tr><td>Age</td><td>21.1 (2.4)</td><td>21.1 (2.1)</td><td>22 (2.5)</td><td>n.s.</td></tr><tr><td>IQ test score</td><td>7.8 (2.6)</td><td>7.3 (2.7)</td><td>7.4 (2.3)</td><td>n.s.</td></tr><tr><td>Monthly cannabis use</td><td>42.8 (31.3)</td><td>51.3 (52.6)</td><td>39.3 (27.8)</td><td>n.s.</td></tr><tr><td>Years of cannabis exposure</td><td>6 (3.1)</td><td>4.8 (1.9)</td><td>6.2 (2.6)</td><td>n.s.</td></tr><tr><td>Monthly alcohol use</td><td>26.2 (17.8)</td><td>23.7 (19.8)</td><td>18.8 (13.5)</td><td>n.s.</td></tr><tr><td>Years of alcohol exposure</td><td>5.3 (2.6)</td><td>4.8 (2.5)</td><td>6.9 (2.7)</td><td>n.s.</td></tr><tr><td>Monthly nicotine use</td><td>214.4 (207.7)</td><td>121.3 (140)</td><td>156 (185.3)</td><td>n.s.</td></tr><tr><td>Years of nicotine exposure</td><td>4.6 (3.8)</td><td>3.5 (4.2)</td><td>4.3 (4)</td><td>n.s.</td></tr></tbody></table><table-wrap-foot><p>Standard deviations in parentheses</p><p>
<italic>n.s</italic>. non-significant difference, <italic>Age</italic> reported in years, <italic>IQ test score</italic> measured by a shortened version of Raven&#x02019;s Standard Progressive Matrices, <italic>Monthly cannabis use</italic> consumption of cannabis cigarettes (joints), <italic>Monthly alcohol use</italic> consumption of alcohol units, <italic>Monthly nicotine use</italic> consumption of cigarettes</p></table-wrap-foot></table-wrap></p><p>The participants were randomly assigned to one out of three experimental conditions: placebo, 5.5&#x000a0;mg or 22&#x000a0;mg THC. The groups were comparable in terms of age, substance use characteristics, and IQ test score. All subjects were required to be regular users (use cannabis at least four times a week, for a minimum of 2&#x000a0;years) and to be native Dutch speakers. The exclusion criteria were as follows: (1) history or presence of an axis I psychiatric disorder (DSM-IV; assessed with the use of the Mini International Neuropsychiatric Interview (M.I.N.I.); Lecrubier et al. <xref ref-type="bibr" rid="CR36">1997</xref>), (2) clinically significant medical disease, (3) use of psychotropic medication, (4) current or previous regular use of other drugs except cannabis (regular use defined as having used a drug more than four times in a lifetime), and (5) abuse of alcohol (more than 14 units a week). Compliance with the inclusion and exclusion criteria was assessed by means of self-report. Additionally, subjects were asked to refrain from caffeine, chocolate, and alcohol 12&#x000a0;h before the experimental session and not to use nicotine 2&#x000a0;h before the study. It was also not allowed to use cannabis within 2&#x000a0;days before the experiment. Participants&#x02019; compliance with these criteria was evaluated by means of a personal interview and the use of a saliva drug test, which detected the recent use of cannabis, morphine, or cocaine (Oral-View&#x02122; Saliva Multi-Drug of Abuse Test; Alfa Scientific Designs, Inc., Poway, CA, U.S.A.).</p><p>From the initial sample of 59 subjects, two male participants withdrew from the study before completing the two creativity tasks&#x02014;one stated personal issues, while the other did not provide any explanation. Another subject experienced anxiety before cannabis administration and had to abort the experiment. In the case of adverse events related to drug administration, one participant reported anxiety, combined with fatigue and nausea, which prevented him from completing the tasks. Moreover, one female subject was excluded from the analysis due to lack of compliance to task requirements (i.e., she refused completing the tasks due to not liking their nature). This left 54 subjects for the final analysis (48 males and 6 females), except for the convergent thinking task (RAT). In this case, one male participant (in the 22 mg THC condition) requested to abort the study due to personal reasons before being able to complete the task, which left only 53 data sets for the RAT analysis.</p></sec><sec id="Sec4"><title>Study drugs</title><p>The active drug substance consisted of the dried, milled, and homogenized flowers of the plant <italic>C. sativa</italic> (variety &#x0201c;Bedrocan&#x0201d;&#x000ae;; 19&#x000a0;% THC). It was obtained from Bedrocan BV (Veendam, The Netherlands) where it was cultivated under standardized conditions according to the requirements of Good Agricultural Practice (GAP). The placebo (variety &#x0201c;Bedrocan&#x0201d;&#x000ae;; &#x0003c;0.5&#x000a0;% THC) used in the study had a moisture content and terpenoid profile (providing the typical smell and taste of cannabis) identical to the active drug. Study medication was prepared by ACE Pharmaceuticals BV (Zeewolde, The Netherlands). For each individual dose, exact amounts of active cannabis and placebo were mixed so that each dose was equal to 250&#x000a0;mg total weight but with varying concentrations of THC (placebo/5.5&#x000a0;mg/22&#x000a0;mg THC). Study medication was stored in a refrigerator (2&#x02013;8&#x000a0;&#x000b0;C) in triple-layer laminated foil pouches (Lamigrip). Shelf life stability under these conditions was determined to be at least 1&#x000a0;year.</p><p>On the study day, each subject received a randomized single dose of cannabis by means of a Volcano&#x000ae; vaporizer (Storz &#x00026; Bickel GmbH, T&#x000fc;ttlingen, Germany)&#x02014;a reliable and safe method of intrapulmonary administration of THC (Hazekamp et al. <xref ref-type="bibr" rid="CR28">2006</xref>; Zuurman et al. <xref ref-type="bibr" rid="CR59">2008</xref>). Cannabis was vaporized at a temperature of 230&#x000a0;&#x000b0;C into a standard Volcano balloon as supplied with the vaporizer. For blinding purposes, the Volcano balloon was covered with a non-transparent plastic bag so that no differences in density of the vapor were visible between dosages.</p><p>When administrating THC by means of vaporizing, it should be taken into account that only part of the dose present in the plant material is vaporized into the balloon (Hazekamp et al. <xref ref-type="bibr" rid="CR28">2006</xref>) and that a portion of the THC inhaled from the balloon is not absorbed by the lungs but is exhaled again (Zuurman et al. <xref ref-type="bibr" rid="CR59">2008</xref>). Therefore, in order to achieve an absorbed dose of approx. 2 and 8&#x000a0;mg THC, we loaded the Volcano vaporizer with 5.5 and 22&#x000a0;mg of THC, respectively. Moreover, since the THC delivery of the Volcano vaporizer and cannabis joints is comparable (Abrams et al. <xref ref-type="bibr" rid="CR1">2007</xref>), the loaded vs. absorbed dose distinction can be applied to smoked cannabis as well.</p><p>During administration, subjects were instructed to inhale deeply and hold their breath for 10&#x000a0;s after each inhalation. They were not allowed to speak during the inhalation period and were required to empty the balloon within 5&#x000a0;min. Subjects had the opportunity to practice the inhalation procedure using an empty balloon before cannabis administration.</p></sec><sec id="Sec5"><title>Shortened Raven&#x02019;s Standard Progressive Matrices (measure of intelligence)</title><p>Individual IQ test scores were determined by means of a reasoning-based intelligence test (Raven et al. <xref ref-type="bibr" rid="CR43">1988</xref>). Each item of this test consists of a pattern or sequence of a diagrammatic puzzle with one piece missing, the task being to complete the pattern or sequence by choosing the correct missing piece from a list of options. The items are getting more difficult as the test taker proceeds through the test. The Standard Progressive Matrices (SPM) test assesses the individual&#x02019;s ability to create perceptual relations and to reason by analogy independent of language and formal schooling. The version of the test used in the study consisted of 14 items.</p></sec><sec id="Sec6"><title>Alternate Uses Task (divergent thinking)</title><p>In this task (Guilford <xref ref-type="bibr" rid="CR25">1967</xref>), participants were asked to list as many possible uses for two common household items (i.e., pen, shoe) as they could. The scoring had four components: <italic>fluency</italic> (the total of all responses), <italic>flexibility</italic> (the number of different categories used; e.g., &#x0201c;household uses&#x0201d;), <italic>originality</italic> (where each response was compared to the responses from the other subjects, responses given by only 5&#x000a0;% of the participants being counted unusual [1 point] and responses given by only 1&#x000a0;% as unique [2 points]), and <italic>elaboration</italic> (referring to the amount of detail; e.g., while a book used as &#x0201c;a doorstop&#x0201d; would count 0, &#x0201c;a doorstop to prevent a door slamming shut in a strong wind&#x0201d; would count 2: 1 point for explanation of door slamming and 1 point for additional detail about the wind). Of these four criteria, the component <italic>flexibility</italic> has been found to be the theoretically most transparent and the empirically most consistent and reliable score (Akbari Chermahini and Hommel <xref ref-type="bibr" rid="CR2">2010</xref>).</p></sec><sec id="Sec7"><title>Remote Associates Task (convergent thinking)</title><p>In this task (developed by Mednick <xref ref-type="bibr" rid="CR38">1962</xref>), participants were presented with three unrelated words (e.g., time, hair, and stretch) and asked to find a common associate (long). The test consisted of 14 items, which were taken from Dutch version of the RAT from Akbari Chermahini et al. (<xref ref-type="bibr" rid="CR3">2012</xref>).</p></sec><sec id="Sec8"><title>Affect grid (subjective measure of mood)</title><p>As in Colzato et al. (<xref ref-type="bibr" rid="CR12">2013</xref>), the current mood of participants was assessed by means of a 9&#x02009;&#x000d7;&#x02009;9 Pleasure&#x02009;&#x000d7;&#x02009;Arousal grid (Russell et al. <xref ref-type="bibr" rid="CR45">1989</xref>).</p></sec><sec id="Sec9"><title>Visual analogue scales (subjective measure of drug effects)</title><p>The subjective effects of cannabis were assessed by means of three scales (horizontal 100-mm lines, the left pole labeled &#x0201c;not at all&#x0201d; and the right &#x0201c;extremely&#x0201d;) referring to &#x0201c;(feeling) high,&#x0201d; &#x0201c;good drug effect,&#x0201d; and &#x0201c;bad drug effect.&#x0201d; Participants were to mark a point at the continuous line to indicate their experience.</p></sec><sec id="Sec10"><title>Design and procedure</title><p>The study used a randomized, double-blind, placebo-controlled, between-groups (placebo vs. 5.5 vs. 22&#x000a0;mg THC) design. All participants were tested individually, and the order of the two creativity tasks&#x02014;AUT and RAT&#x02014;was counterbalanced. Upon arrival, the subjects were asked to complete the SPM test within 10&#x000a0;min. Afterward, the study drug was administered. Six minutes after cannabis administration, participants were required to indicate the subjective effects of the drugs by means of the visual analogue scales (VAS). This assessment of the effects of the drugs was then repeated twice&#x02014;before and after the completion of the two creativity tasks (35 and 60&#x000a0;min after administration). Participants were provided with both the AUT and RAT in printed form (in the time window between 35 and 60&#x000a0;min after administration) and had 10&#x000a0;min to complete each task. In addition, in order to evaluate the subjective perception of mood, subjects were required to rate their mood on the Affect grid after the completion of each creativity task (at 48 and 60&#x000a0;min after administration).</p></sec><sec id="Sec11"><title>Statistical analysis</title><p>Scores from mood assessments and VAS, together with the five measures from the two creativity tasks (fluency, flexibility, originality, and elaboration scores from the AUT; the number of correct items from the RAT) were calculated for each subject. The results of the AUT were rated by two independent readers, blinded to the conditions (Cronbach&#x02019;s alpha&#x02009;=&#x02009;1.00 [fluency]; 0.87 [flexibility]; 0.94 [originality]; 0.9 [elaboration]). The final scores were the means of both ratings. All measures were analyzed separately. In the case of the AUT, RAT, and IQ test scores, age, and substance use data, between-groups ANOVAs were run with condition (placebo vs. 5.5 vs. 22&#x000a0;mg THC) as between-groups factor. Data regarding sex was analyzed with the use of a Pearson&#x02019;s chi-squared test. Mood and VAS scores were analyzed by means of repeated-measures ANOVAs with time after cannabis administration (48 vs. 60&#x000a0;min. for mood; 6 vs. 35 vs. 60&#x000a0;min. for VAS) as a within-subjects factor and condition as a between-groups factor. Post hoc multiple comparisons <italic>t</italic> tests were applied with Bonferroni correction. A significance level of <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 was adopted for all tests.</p></sec></sec><sec id="Sec12" sec-type="results"><title>Results</title><sec id="Sec13"><title>Demographic and substance use data</title><p>No significant main effects of condition were found in the case of age (<italic>F</italic>(2, 51)&#x02009;=&#x02009;0.74, <italic>p</italic>&#x02009;=&#x02009;0.482), IQ test score (<italic>F</italic>(2, 51)&#x02009;=&#x02009;0.159, <italic>p</italic>&#x02009;=&#x02009;0.854), monthly cannabis use (<italic>F</italic>(2, 51)&#x02009;=&#x02009;0.453, <italic>p</italic>&#x02009;=&#x02009;0.639), years of cannabis exposure (<italic>F</italic>(2, 51)&#x02009;=&#x02009;1.433, <italic>p</italic>&#x02009;=&#x02009;0.248), monthly alcohol use (<italic>F</italic>(2, 51)&#x02009;=&#x02009;0.855, <italic>p</italic>&#x02009;=&#x02009;0.431), years of alcohol exposure (<italic>F</italic>(2, 51)&#x02009;=&#x02009;3.027, <italic>p</italic>&#x02009;=&#x02009;0.057), monthly nicotine use (<italic>F</italic>(2, 51)&#x02009;=&#x02009;1.231, <italic>p</italic>&#x02009;=&#x02009;0.3), and years of nicotine exposure (<italic>F</italic>(2, 51)&#x02009;=&#x02009;0.383, <italic>p</italic>&#x02009;=&#x02009;0.684). However, the experimental conditions significantly differed by sex (<italic>&#x003c7;</italic><sup><italic>2</italic></sup>(2, <italic>N</italic>&#x02009;=&#x02009;54)&#x02009;=&#x02009;7.875, <italic>p</italic>&#x02009;=&#x02009;0.019); see Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.</p></sec><sec id="Sec14"><title>Creativity tasks</title><p>Overall task performance in the AUT and RAT was comparable to studies without pharmacological interventions (e.g., Akbari Chermahini and Hommel <xref ref-type="bibr" rid="CR2">2010</xref>); see Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>
<italic>Bar graphs</italic> showing mean scores for the four components of the Alternate Uses Task (AUT; <italic>fluency</italic>, <italic>flexibility</italic>, <italic>originality</italic>, and <italic>elaboration</italic>) for each experimental group. The <italic>asterisk</italic> indicates a significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) difference between the 5.5 and 22&#x000a0;mg THC conditions and between the placebo and 22&#x000a0;mg THC conditions. <italic>Error bars</italic> represent SE of the mean</p></caption><graphic xlink:href="213_2014_3749_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>Means, SD, and ANOVA results for the four components of the Alternate Uses Task (AUT; <italic>fluency</italic>, <italic>flexibility</italic>, <italic>originality</italic>, and <italic>elaboration</italic>) and the number of correct items from the Remote Associates Task (RAT), for each experimental group</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Placebo</th><th>5.5&#x000a0;mg THC</th><th>22&#x000a0;mg THC</th><th>
<italic>F</italic> value</th><th>
<italic>p</italic> value</th><th>
<italic>&#x003b7;</italic>
<sup><italic>2</italic></sup>
<sub><italic>p</italic></sub>
</th><th>
<italic>MSE</italic>
</th></tr></thead><tbody><tr><td>AUT</td><td/><td/><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Fluency*</td><td>29.2 (9.5)</td><td>30.6 (9.2)</td><td>19.6 (9)</td><td char="." align="char">7.378</td><td char="." align="char">0.002</td><td char="." align="char">0.224</td><td char="." align="char">86.615</td></tr><tr><td>&#x02003;Flexibility*</td><td>22.3 (4.9)</td><td>23.6 (6.2)</td><td>16 (7.2)</td><td char="." align="char">7.708</td><td char="." align="char">0.001</td><td char="." align="char">0.232</td><td char="." align="char">38.683</td></tr><tr><td>&#x02003;Originality*</td><td>21.2 (8.4)</td><td>27.5 (11.5)</td><td>14.1 (8.1)</td><td char="." align="char">8.952</td><td char="." align="char">&#x0003c;0.001</td><td char="." align="char">0.26</td><td char="." align="char">90.63</td></tr><tr><td>&#x02003;Elaboration</td><td>2.5 (2.8)</td><td>1.2 (1.6)</td><td>1.2 (1.6)</td><td char="." align="char">2.152</td><td char="." align="char">0.127</td><td char="." align="char">0.078</td><td char="." align="char">4.552</td></tr><tr><td>RAT</td><td>4.8 (2.3)</td><td>4.5 (2.8)</td><td>4.9 (3.6)</td><td char="." align="char">0.116</td><td char="." align="char">0.891</td><td char="." align="char">0.005</td><td char="." align="char">8.904</td></tr></tbody></table><table-wrap-foot><p>*<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 (significant difference between 5.5 and 22&#x000a0;mg THC, and between placebo and 22&#x000a0;mg THC)</p></table-wrap-foot></table-wrap></p><sec id="Sec15"><title>Divergent thinking</title><p>Significant main effects of condition were found on fluency (<italic>F</italic>(2, 51)&#x02009;=&#x02009;7.378, <italic>p</italic>&#x02009;=&#x02009;0.002), flexibility (<italic>F</italic>(2, 51)&#x02009;=&#x02009;7.708, <italic>p</italic>&#x02009;=&#x02009;0.001), and originality (<italic>F</italic>(2, 51)&#x02009;=&#x02009;8.952, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), but not on elaboration (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05).</p><p>As expected, post hoc multiple comparisons revealed that participants in the 22&#x000a0;mg THC condition showed significantly reduced scores, as compared to placebo and 5.5&#x000a0;mg THC, respectively, for fluency (<italic>t</italic>(34)&#x02009;=&#x02009;3.072, <italic>p</italic>&#x02009;=&#x02009;0.01; <italic>t</italic>(34)&#x02009;=&#x02009;3.582, <italic>p</italic>&#x02009;=&#x02009;0.003), flexibility (<italic>t</italic>(34)&#x02009;=&#x02009;3.061, <italic>p</italic>&#x02009;=&#x02009;0.011; <italic>t</italic>(34)&#x02009;=&#x02009;3.367, <italic>p</italic>&#x02009;=&#x02009;0.002), and originality (<italic>t</italic>(34)&#x02009;=&#x02009;2.584, <italic>p</italic>&#x02009;=&#x02009;0.045; <italic>t</italic>(34)&#x02009;=&#x02009;4.021, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). However, contrary to expectations, subjects in the 5.5&#x000a0;mg THC condition did not display any significant increases over placebo, on any of the AUT components (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05).</p><p>Moreover, in order to test whether sex differences had impact on the observed results and match the groups for sex, we repeated the analysis after the exclusion of all female subjects. Significant main effects were retained for fluency (<italic>F</italic>(2, 45)&#x02009;=&#x02009;5.774, <italic>p</italic>&#x02009;=&#x02009;0.006), flexibility (<italic>F</italic>(2, 45)&#x02009;=&#x02009;6.325, <italic>p</italic>&#x02009;=&#x02009;0.004), and originality (<italic>F</italic>(2, 45)&#x02009;=&#x02009;7.641, <italic>p</italic>&#x02009;=&#x02009;0.001).</p></sec><sec id="Sec16"><title>Convergent thinking</title><p>Contrary to expectations, there was no main effect of condition on the number of correct items from the RAT (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05).</p></sec></sec><sec id="Sec17"><title>Subjective measures of drug effects and mood</title><sec id="Sec18"><title>Drug effects</title><p>Overall, only the rating of &#x0201c;high&#x0201d; showed a main effect of time after cannabis administration (with Huynh-Feldt correction; <italic>F</italic>(1.862, 93.109)&#x02009;=&#x02009;15.777, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001). However, significant main effects of condition were found on all three scores: high (<italic>F</italic>(2, 50)&#x02009;=&#x02009;11.656, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), good drug effect (<italic>F</italic>(2, 50)&#x02009;=&#x02009;8.701, <italic>p</italic>&#x02009;=&#x02009;0.001), and bad drug effect (<italic>F</italic>(2, 50)&#x02009;=&#x02009;6.507, <italic>p</italic>&#x02009;=&#x02009;0.003). There were no significant interaction effects (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05).</p><p>Post hoc multiple comparisons revealed that subjects in the placebo condition showed significantly lower ratings of high, compared to the 5.5&#x000a0;mg (<italic>t</italic>(34)&#x02009;=&#x02009;2.95, <italic>p</italic>&#x02009;=&#x02009;0.006) and 22&#x000a0;mg THC groups (<italic>t</italic>(34)&#x02009;=&#x02009;4.49, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001); see Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>. Moreover, the ratings of good drug effect in the placebo condition were significantly lower than in the 5.5&#x000a0;mg (<italic>t</italic>(34)&#x02009;=&#x02009;3.535, <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) and 22&#x000a0;mg THC groups (<italic>t</italic>(34)&#x02009;=&#x02009;2.365, <italic>p</italic>&#x02009;=&#x02009;0.023); see Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. In the case of both high and good drug effect, no significant differences were found between the scores in the 5.5&#x000a0;mg and 22&#x000a0;mg THC groups (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05). Conversely, in the case of the ratings of bad drug effect, participants in the 22&#x000a0;mg THC condition demonstrated significantly increased scores, compared to placebo (<italic>t</italic>(34)&#x02009;=&#x02009;3.48, <italic>p</italic>&#x02009;=&#x02009;0.006) and 5.5&#x000a0;mg THC (<italic>t</italic>(34)&#x02009;=&#x02009;3.141, <italic>p</italic>&#x02009;=&#x02009;0.012); see Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. In addition, the ratings of bad drug effect did not significantly differ between the placebo and 5.5&#x000a0;mg THC conditions (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05).<fig id="Fig2"><label>Fig. 2</label><caption><p>Mean subjective high (rated as a percentage) experienced in each experimental group as a function of time after cannabis administration. <italic>Symbols</italic> indicate a significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) difference between the 22&#x000a0;mg THC and placebo conditions (*) and between the 5.5&#x000a0;mg THC and placebo conditions (**). <italic>Error bars</italic> represent SE of the mean</p></caption><graphic xlink:href="213_2014_3749_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Mean subjective good drug effect (rated as a percentage) experienced in each experimental group as a function of time after cannabis administration. <italic>Symbols</italic> indicate a significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) difference between the 22&#x000a0;mg THC and placebo conditions (*) and between the 5.5&#x000a0;mg THC and placebo conditions (**). <italic>Error bars</italic> represent SE of the mean</p></caption><graphic xlink:href="213_2014_3749_Fig3_HTML" id="MO3"/></fig><fig id="Fig4"><label>Fig. 4</label><caption><p>Mean subjective bad drug effect (rated as a percentage) experienced in each experimental group as a function of time after cannabis administration. <italic>Symbols</italic> indicate a significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) difference between the placebo and 22&#x000a0;mg THC conditions (*) and between the 5.5 and 22&#x000a0;mg THC conditions (**). <italic>Error bars</italic> represent SE of the mean</p></caption><graphic xlink:href="213_2014_3749_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec19"><title>Mood</title><p>There were no main effects of time after cannabis administration on the ratings of pleasure or arousal (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05). Moreover, mood ratings in the placebo (6.3 vs. 6.2 for pleasure; 5.1 vs. 5 for arousal), 5.5&#x000a0;mg (7.1 vs. 7 for pleasure; 5.5 vs. 5.2 for arousal), and 22&#x000a0;mg THC (6.1 vs. 6.4 for pleasure; 4.8 vs. 4.7 for arousal) conditions did not show significant main effects of condition on pleasure or arousal (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05). There were no significant interaction effects (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05).</p></sec></sec></sec><sec id="Sec20" sec-type="discussion"><title>Discussion</title><p>Our findings demonstrate that a high dose of vaporized cannabis (22&#x000a0;mg THC) impairs divergent thinking in regular cannabis users, in comparison to a low dose (5.5&#x000a0;mg THC) and placebo cannabis preparation. This is reflected in the decreased scores for fluency, flexibility, and originality of responses of participants in the high-dose condition. However, contrary to expectations, a low dose of cannabis did not enhance divergent thinking in chronic cannabis users: Individuals in the low-dose group did not significantly outperform subjects in the placebo group on any of the components of the AUT. Moreover, convergent thinking appears to be unaffected by either a low or high dose of cannabis, as condition had no impact on the numbers of correct RAT items.</p><p>Although the conclusions are limited by a between-groups design, the finding that administration of a high, but not low, dose of cannabis impairs divergent thinking performance of regular cannabis users may suggest that DA release in the striata of participants in the high-dose condition (Bossong et al. <xref ref-type="bibr" rid="CR9">2009</xref>; Kuepper et al. <xref ref-type="bibr" rid="CR35">2013</xref>) exceeded the threshold for optimal performance (Akbari Chermahini and Hommel <xref ref-type="bibr" rid="CR2">2010</xref>). This is in line with neuroscientific considerations that point to a homeostatic function of DA in regulating the balance between opposing cognitive control states&#x02014;flexibility and stability (Cools et al. <xref ref-type="bibr" rid="CR14">2009</xref>; Cools and D&#x02019;Esposito <xref ref-type="bibr" rid="CR13">2011</xref>). Flexibility refers to the ability to effectively switch between cognitive representations for the purpose of choosing the best alternatives, while the function of stability is to promote constancy of representations in spite of interference (Cools and D&#x02019;Esposito <xref ref-type="bibr" rid="CR13">2011</xref>). Consequently, keeping in mind the effect of cannabis on inhibition (Ramaekers et al. <xref ref-type="bibr" rid="CR41">2006</xref>; Ramaekers et al. <xref ref-type="bibr" rid="CR42">2009</xref>), it is safe to assume that individuals in the high-dose condition experienced a reduction in inhibitory control after cannabis administration. Although this should promote a control state with weak top-down guidance allowing for flexible updating of information (Hommel <xref ref-type="bibr" rid="CR31">2012</xref>; Colzato et al. <xref ref-type="bibr" rid="CR11">2012</xref>), supra-optimal levels of DA in the striatum have been found to stimulate flexibility to the point that it surpasses the threshold for optimal performance, inducing distractibility as a result (see Cools and D&#x02019;Esposito <xref ref-type="bibr" rid="CR13">2011</xref>). Accordingly, it is possible that the observed impairment of divergent thinking in the high-dose condition was the result of this process. Presumably, induction of a control state with weak top-down guidance is a necessary, but not sufficient, prerequisite for enhanced divergent thinking performance. Conversely, excessively potent cannabis may disturb the delicate balance between stability and flexibility by stimulating flexibility to its extreme, hence impairing divergent thinking.</p><p>In addition, from a more motivational perspective, it is possible that a high dose of cannabis induces the phenomenon of &#x0201c;ego-depletion&#x0201d; (i.e., exhausts the limited cognitive resources and motivation required for cognitive control operations; Baumeister et al. <xref ref-type="bibr" rid="CR4">1998</xref>; Inzlicht and Schmeichel <xref ref-type="bibr" rid="CR32">2012</xref>). This seems probable taking into account the observation that participants in the high-dose condition experienced more intense unpleasant subjective effects of cannabis, than those in the low-dose and placebo groups. In line with that, research points to anxiety, paranoia, delusions, and mental disorganization as frequent adverse effects of cannabis intoxication (Green et al. <xref ref-type="bibr" rid="CR24">2003</xref>; D&#x02019;Souza et al. <xref ref-type="bibr" rid="CR19">2004</xref>). Therefore, the various undesirable forms of distraction induced by cannabis could have drained the control resources of individuals in the high-dose condition. In other words, it is possible that the need to exert self-control over the adverse effects of cannabis leads to a reduction in motivation and available cognitive resources required for subsequent optimal divergent thinking performance (Inzlicht and Schmeichel <xref ref-type="bibr" rid="CR32">2012</xref>).</p><p>In the case of the low-dose group, the lack of enhancement of divergent thinking does not provide support for the idea that a low dose of cannabis can eliminate cognitive impairments caused by regular use (Weckowicz et al. <xref ref-type="bibr" rid="CR57">1975</xref>; Kelleher et al. <xref ref-type="bibr" rid="CR33">2004</xref>). Nevertheless, since the performance of subjects in the low-dose and placebo groups was comparable in the case of the AUT, it may be assumed that the lack of cannabis-induced cognitive deterioration in the low-dose condition was indicative of the tolerance of regular cannabis users to the effects of the drug (Hart et al. <xref ref-type="bibr" rid="CR26">2001</xref>; Ramaekers et al. <xref ref-type="bibr" rid="CR42">2009</xref>; Hart et al. <xref ref-type="bibr" rid="CR27">2010</xref>; Theunissen et al. <xref ref-type="bibr" rid="CR53">2012</xref>). Furthermore, it is possible that the similar level of performance of both groups reflects their maximal potential for divergent thinking. Research indicates that placebo effects are able to stimulate subcortical DA release (Scott et al. <xref ref-type="bibr" rid="CR49">2007</xref>; Scott et al. <xref ref-type="bibr" rid="CR50">2008</xref>). Possibly, administration of a low dose of cannabis resulted in a comparable dopaminergic response as in the case of the placebo (Bossong et al. <xref ref-type="bibr" rid="CR9">2009</xref>; Kuepper et al. <xref ref-type="bibr" rid="CR35">2013</xref>). This seems plausible considering the fact that the placebo cannabis preparation used in the study was identical in terms of smell and taste to actual cannabis. As such, it had more potential to produce a placebo effect. In addition, the minimal amount of THC present in the placebo might have also affected DA release to some extent. Consequently, the subcortical DA levels of individuals in both the low-dose and placebo conditions could have been within the range for optimal divergent thinking performance (Akbari Chermahini and Hommel <xref ref-type="bibr" rid="CR2">2010</xref>).</p><sec id="Sec21"><title>Limitations</title><p>Although the most recent investigation into the link between cannabis and convergent thinking suggested a potentially detrimental effect of cannabis intoxication on this process (Schafer et al. <xref ref-type="bibr" rid="CR47">2012</xref>), our study failed to detect any impact on RAT performance. Perhaps, our version of the task with 14 items was not sensitive enough to identify potential cannabis-induced impairments. Moreover, an important limitation is the between-groups design of the study. Consequently, it is possible that particular characteristics of the subject sample could have altered the effects of the drug. Specifically, the difference in sex between the conditions seems as a likely candidate in this regard (Crane et al. <xref ref-type="bibr" rid="CR15">2013</xref>). In addition, research points to genetic predispositions like polymorphism of the CB<sub>1</sub> receptor gene (Beng-Choon et al. <xref ref-type="bibr" rid="CR5">2011</xref>; Stadelman et al. <xref ref-type="bibr" rid="CR51">2011</xref>), or the catechol-<italic>O</italic>-methyltransferase (COMT) gene (Schulz et al. <xref ref-type="bibr" rid="CR48">2012</xref>), as other factors which might modulate the cognitive effects of cannabis intoxication.</p><p>Another issue is related to the causal relation between the observed results and THC. In spite of the fact that application of cannabis, instead of pure THC, provides the benefit of a higher ecological validity of the study, the use of plant material could have influenced the findings. Specifically, terpenoids, which are the compounds responsible for the characteristic smell and taste of cannabis, have been shown to interact with cannabinoids to produce various synergistic effects (see Russo <xref ref-type="bibr" rid="CR46">2011</xref>). However, even if that was the case in our experiment, the terpenoid profile was comparable between the different doses, including the placebo cannabis preparation. Consequently, any potential terpenoid-cannabinoid interactions were controlled for. Unfortunately, the study lacked a measurement of THC blood plasma levels, which would allow for evaluating the relation between THC in the bloodstream and task performance. Furthermore, since the number of inhalations from the Volcano balloon and the duration of inhalations were not standardized, it is likely that this resulted in large differences in absorbed THC between subjects. In addition, the saliva test used in our experiment provided only an estimate of recent use. Possibly, the compliance of subjects with no-consumption criteria should instead be verified by examining the urinary levels of THC metabolites (11-COOH-THC), which is capable of detecting intoxication over a longer period of time. Moreover, the lack of testing for alcohol intoxication can be considered another limitation in evaluating the compliance of participants with no-consumption criteria.</p></sec><sec id="Sec22"><title>Conclusion</title><p>The findings indicate that administration of cannabis with a high THC content to regular cannabis users is detrimental for divergent thinking, while less potent cannabis does not seem to enhance this important component of creativity. The available evidence allows only for a speculation about the presence of these effects in a group of drug-na&#x000ef;ve individuals, or occasional cannabis users. In any case, it can be claimed that the phenomenological experience of a person intoxicated with cannabis might not necessarily reflect his or her actual performance. In particular, the frequently reported feeling of heightened creativity could be an illusion. In other words, smoking a joint may not be the best choice when in need of breaking the &#x0201c;writer&#x02019;s block,&#x0201d; or overcoming other artistic inhibitions, and smoking several of them might actually be counter-productive.</p></sec></sec></body><back><ack><p>We would like to thank Ms. Linda van der Hulst from the Central Pharmacy of the Leiden University Medical Center for her assistance in preparing the study and our subjects for participation.</p><sec id="d30e1617"><title>Conflict of interest</title><p>Dr. Arno Hazekamp receives a salary from Bedrocan BV&#x02014;the company which provided the study drugs. The authors have full control of all primary data, and they agree to allow the journal to review their data if requested.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>DI</given-names></name><name><surname>Vizoso</surname><given-names>HP</given-names></name><name><surname>Shade</surname><given-names>SB</given-names></name><name><surname>Jay</surname><given-names>C</given-names></name><name><surname>Kelly</surname><given-names>ME</given-names></name><name><surname>Benowitz</surname><given-names>NL</given-names></name></person-group><article-title>Vaporization as a smokeless cannabis delivery system: a pilot study</article-title><source>Clin Pharmacol Ther</source><year>2007</year><volume>82</volume><fpage>572</fpage><lpage>578</lpage><pub-id pub-id-type="doi">10.1038/sj.clpt.6100200</pub-id><pub-id pub-id-type="pmid">17429350</pub-id></element-citation></ref><ref id="CR2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbari Chermahini</surname><given-names>S</given-names></name><name><surname>Hommel</surname><given-names>B</given-names></name></person-group><article-title>The (b)link between creativity and dopamine: spontaneous eye blink rates predict and dissociate divergent and convergent thinking</article-title><source>Cognition</source><year>2010</year><volume>115</volume><fpage>458</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.cognition.2010.03.007</pub-id><pub-id pub-id-type="pmid">20334856</pub-id></element-citation></ref><ref id="CR3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbari Chermahini</surname><given-names>S</given-names></name><name><surname>Hickendorff</surname><given-names>M</given-names></name><name><surname>Hommel</surname><given-names>B</given-names></name></person-group><article-title>Development and validity of a Dutch version of the remote associates task: an item-response theory approach</article-title><source>Think Skills Creat</source><year>2012</year><volume>7</volume><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1016/j.tsc.2012.02.003</pub-id></element-citation></ref><ref id="CR4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumeister</surname><given-names>RF</given-names></name><name><surname>Bratslavsky</surname><given-names>E</given-names></name><name><surname>Muraven</surname><given-names>M</given-names></name><name><surname>Tice</surname><given-names>DM</given-names></name></person-group><article-title>Ego depletion: is the active self a limited resource?</article-title><source>J Pers Soc Psychol</source><year>1998</year><volume>74</volume><fpage>1252</fpage><lpage>1265</lpage><pub-id pub-id-type="doi">10.1037/0022-3514.74.5.1252</pub-id><pub-id pub-id-type="pmid">9599441</pub-id></element-citation></ref><ref id="CR5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beng-Choon</surname><given-names>H</given-names></name><name><surname>Wassink</surname><given-names>TH</given-names></name><name><surname>Ziebell</surname><given-names>S</given-names></name><name><surname>Andreasen</surname><given-names>NC</given-names></name></person-group><article-title>Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia</article-title><source>Schizophr Res</source><year>2011</year><volume>128</volume><fpage>66</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2011.02.021</pub-id><pub-id pub-id-type="pmid">21420833</pub-id></element-citation></ref><ref id="CR6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Block</surname><given-names>RI</given-names></name><name><surname>Farinpour</surname><given-names>R</given-names></name><name><surname>Braverman</surname><given-names>K</given-names></name></person-group><article-title>Acute effects of marijuana on cognition: relationships to chronic effects and smoking techniques</article-title><source>Pharmacol Biochem Behav</source><year>1992</year><volume>43</volume><fpage>907</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1016/0091-3057(92)90424-E</pub-id><pub-id pub-id-type="pmid">1448485</pub-id></element-citation></ref><ref id="CR7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloomfield</surname><given-names>MA</given-names></name><name><surname>Morgan</surname><given-names>CJ</given-names></name><name><surname>Egerton</surname><given-names>A</given-names></name><name><surname>Kapur</surname><given-names>S</given-names></name><name><surname>Curran</surname><given-names>HV</given-names></name><name><surname>Howes</surname><given-names>OD</given-names></name></person-group><article-title>Dopaminergic function in cannabis users and its relationship to cannabis-induced psychotic symptoms</article-title><source>Biol Psychiatry</source><year>2014</year><volume>75</volume><fpage>470</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2013.05.027</pub-id><pub-id pub-id-type="pmid">23820822</pub-id></element-citation></ref><ref id="CR8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bogacz</surname><given-names>R</given-names></name></person-group><article-title>Optimal decision-making theories: linking neurobiology with behaviour</article-title><source>Trends Cogn Sci</source><year>2007</year><volume>11</volume><fpage>118</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1016/j.tics.2006.12.006</pub-id><pub-id pub-id-type="pmid">17276130</pub-id></element-citation></ref><ref id="CR9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bossong</surname><given-names>MG</given-names></name><name><surname>van Berckel</surname><given-names>BN</given-names></name><name><surname>Boellaard</surname><given-names>R</given-names></name><name><surname>Zuurman</surname><given-names>L</given-names></name><name><surname>Schuit</surname><given-names>RC</given-names></name><name><surname>Windhorst</surname><given-names>AD</given-names></name><name><surname>van Gerven</surname><given-names>JM</given-names></name><name><surname>Ramsey</surname><given-names>NF</given-names></name><name><surname>Lammertsma</surname><given-names>AA</given-names></name><name><surname>Kahn</surname><given-names>RS</given-names></name></person-group><article-title>Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum</article-title><source>Neuropsychopharmacology</source><year>2009</year><volume>34</volume><fpage>759</fpage><lpage>766</lpage><pub-id pub-id-type="doi">10.1038/npp.2008.138</pub-id><pub-id pub-id-type="pmid">18754005</pub-id></element-citation></ref><ref id="CR10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourassa</surname><given-names>M</given-names></name><name><surname>Vaugeois</surname><given-names>P</given-names></name></person-group><article-title>Effects of marijuana use on divergent thinking</article-title><source>Creat Res J</source><year>2001</year><volume>13</volume><fpage>411</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1207/S15326934CRJ1334_18</pub-id></element-citation></ref><ref id="CR11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colzato</surname><given-names>LS</given-names></name><name><surname>Ozturk</surname><given-names>A</given-names></name><name><surname>Hommel</surname><given-names>B</given-names></name></person-group><article-title>Meditate to create: the impact of focused-attention and open-monitoring training on convergent and divergent thinking</article-title><source>Front Psychol</source><year>2012</year><volume>3</volume><fpage>116</fpage><pub-id pub-id-type="pmid">22529832</pub-id></element-citation></ref><ref id="CR12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colzato</surname><given-names>LS</given-names></name><name><surname>Szapora</surname><given-names>A</given-names></name><name><surname>Pannekoek</surname><given-names>JN</given-names></name><name><surname>Hommel</surname><given-names>B</given-names></name></person-group><article-title>The impact of physical exercise on convergent and divergent thinking</article-title><source>Front Hum Neurosci</source><year>2013</year><volume>7</volume><fpage>824</fpage><pub-id pub-id-type="pmid">24348370</pub-id></element-citation></ref><ref id="CR13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cools</surname><given-names>R</given-names></name><name><surname>D&#x02019;Esposito</surname><given-names>M</given-names></name></person-group><article-title>Inverted-U-shaped dopamine actions on human working memory and cognitive control</article-title><source>Biol Psychiatry</source><year>2011</year><volume>69</volume><fpage>e113</fpage><lpage>e125</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.03.028</pub-id><pub-id pub-id-type="pmid">21531388</pub-id></element-citation></ref><ref id="CR14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cools</surname><given-names>R</given-names></name><name><surname>Frank</surname><given-names>MJ</given-names></name><name><surname>Gibbs</surname><given-names>SE</given-names></name><name><surname>Miyakawa</surname><given-names>A</given-names></name><name><surname>Jagust</surname><given-names>W</given-names></name><name><surname>D&#x02019;Esposito</surname><given-names>M</given-names></name></person-group><article-title>Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration</article-title><source>J Neurosci</source><year>2009</year><volume>29</volume><fpage>1538</fpage><lpage>1543</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.4467-08.2009</pub-id><pub-id pub-id-type="pmid">19193900</pub-id></element-citation></ref><ref id="CR15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crane</surname><given-names>NA</given-names></name><name><surname>Schuster</surname><given-names>RM</given-names></name><name><surname>Gonzalez</surname><given-names>R</given-names></name></person-group><article-title>Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users</article-title><source>J Int Neuropsychol Soc</source><year>2013</year><volume>19</volume><fpage>1009</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1017/S135561771300088X</pub-id><pub-id pub-id-type="pmid">23962414</pub-id></element-citation></ref><ref id="CR16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Curran</surname><given-names>HV</given-names></name><name><surname>Brignell</surname><given-names>C</given-names></name><name><surname>Fletcher</surname><given-names>S</given-names></name><name><surname>Middleton</surname><given-names>P</given-names></name><name><surname>Henry</surname><given-names>J</given-names></name></person-group><article-title>Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users</article-title><source>Psychopharmacology (Berl)</source><year>2002</year><volume>164</volume><fpage>61</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1007/s00213-002-1169-0</pub-id><pub-id pub-id-type="pmid">12373420</pub-id></element-citation></ref><ref id="CR17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Dreu</surname><given-names>CKW</given-names></name><name><surname>Baas</surname><given-names>M</given-names></name><name><surname>Nijstad</surname><given-names>BA</given-names></name></person-group><article-title>Hedonic tone and activation level in the mood&#x02013;creativity link: toward a dual pathway to creativity model</article-title><source>J Pers Soc Psychol</source><year>2008</year><volume>94</volume><fpage>739</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1037/0022-3514.94.5.739</pub-id><pub-id pub-id-type="pmid">18444736</pub-id></element-citation></ref><ref id="CR18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Dreu</surname><given-names>CKW</given-names></name><name><surname>Nijstad</surname><given-names>BA</given-names></name><name><surname>Baas</surname><given-names>M</given-names></name><name><surname>Wolsink</surname><given-names>I</given-names></name><name><surname>Roskes</surname><given-names>M</given-names></name></person-group><article-title>Working memory benefits creative insight, musical improvisation, and original ideation through maintained task-focused attention</article-title><source>Pers Soc Psychol Bull</source><year>2012</year><volume>38</volume><fpage>656</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.1177/0146167211435795</pub-id><pub-id pub-id-type="pmid">22301457</pub-id></element-citation></ref><ref id="CR19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Souza</surname><given-names>DC</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><name><surname>MacDougall</surname><given-names>L</given-names></name><name><surname>Ammerman</surname><given-names>Y</given-names></name><name><surname>Cooper</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>YT</given-names></name><name><surname>Braley</surname><given-names>G</given-names></name><name><surname>Gueorguieva</surname><given-names>R</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name></person-group><article-title>The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis</article-title><source>Neuropsychopharmacology</source><year>2004</year><volume>29</volume><fpage>1558</fpage><lpage>1572</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300496</pub-id><pub-id pub-id-type="pmid">15173844</pub-id></element-citation></ref><ref id="CR20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Souza</surname><given-names>DC</given-names></name><name><surname>Ranganathan</surname><given-names>M</given-names></name><name><surname>Braley</surname><given-names>G</given-names></name><name><surname>Gueorguieva</surname><given-names>R</given-names></name><name><surname>Zimolo</surname><given-names>Z</given-names></name><name><surname>Cooper</surname><given-names>T</given-names></name><name><surname>Perry</surname><given-names>E</given-names></name><name><surname>Krystal</surname><given-names>JH</given-names></name></person-group><article-title>Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis</article-title><source>Neuropsychopharmacology</source><year>2008</year><volume>33</volume><fpage>2505</fpage><lpage>2516</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1301643</pub-id><pub-id pub-id-type="pmid">18185500</pub-id></element-citation></ref><ref id="CR21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fattore</surname><given-names>L</given-names></name><name><surname>Melis</surname><given-names>M</given-names></name><name><surname>Fadda</surname><given-names>P</given-names></name><name><surname>Pistis</surname><given-names>M</given-names></name><name><surname>Fratta</surname><given-names>W</given-names></name></person-group><article-title>The endocannabinoid system and nondrug rewarding behaviours</article-title><source>Exp Neurol</source><year>2010</year><volume>224</volume><fpage>23</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2010.03.020</pub-id><pub-id pub-id-type="pmid">20353776</pub-id></element-citation></ref><ref id="CR22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Ruiz</surname><given-names>J</given-names></name><name><surname>Hern&#x000e1;ndez</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>JA</given-names></name></person-group><article-title>Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders</article-title><source>CNS Neurosci Ther</source><year>2010</year><volume>16</volume><fpage>e72</fpage><lpage>e91</lpage><pub-id pub-id-type="doi">10.1111/j.1755-5949.2010.00144.x</pub-id><pub-id pub-id-type="pmid">20406253</pub-id></element-citation></ref><ref id="CR23"><mixed-citation publication-type="other">Friendly M (2014) Power. In: Power analysis for ANOVA designs. <ext-link ext-link-type="uri" xlink:href="http://www.math.yorku.ca/scs/online/power">http://www.math.yorku.ca/scs/online/power</ext-link>. Accessed 11 Sep 2014</mixed-citation></ref><ref id="CR24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>B</given-names></name><name><surname>Kavanagh</surname><given-names>D</given-names></name><name><surname>Young</surname><given-names>R</given-names></name></person-group><article-title>Being stoned: a review of self-reported cannabis effects</article-title><source>Drug Alcohol Rev</source><year>2003</year><volume>22</volume><fpage>453</fpage><lpage>460</lpage><pub-id pub-id-type="doi">10.1080/09595230310001613976</pub-id><pub-id pub-id-type="pmid">14660135</pub-id></element-citation></ref><ref id="CR25"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Guilford</surname><given-names>JP</given-names></name></person-group><source>The nature of human intelligence</source><year>1967</year><publisher-loc>New York</publisher-loc><publisher-name>McGraw-Hill</publisher-name></element-citation></ref><ref id="CR26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>CL</given-names></name><name><surname>van Gorp</surname><given-names>W</given-names></name><name><surname>Haney</surname><given-names>M</given-names></name><name><surname>Foltin</surname><given-names>RW</given-names></name><name><surname>Fischman</surname><given-names>MW</given-names></name></person-group><article-title>Effects of acute smoked marijuana on complex cognitive performance</article-title><source>Neuropsychopharmacology</source><year>2001</year><volume>25</volume><fpage>757</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1016/S0893-133X(01)00273-1</pub-id><pub-id pub-id-type="pmid">11682259</pub-id></element-citation></ref><ref id="CR27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hart</surname><given-names>CL</given-names></name><name><surname>Ilan</surname><given-names>AB</given-names></name><name><surname>Gevins</surname><given-names>A</given-names></name><name><surname>Gunderson</surname><given-names>EW</given-names></name><name><surname>Role</surname><given-names>K</given-names></name><name><surname>Colley</surname><given-names>J</given-names></name><name><surname>Foltin</surname><given-names>RW</given-names></name></person-group><article-title>Neurophysiological and cognitive effects of smoked marijuana in frequent users</article-title><source>Pharmacol Biochem Behav</source><year>2010</year><volume>96</volume><fpage>333</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.pbb.2010.06.003</pub-id><pub-id pub-id-type="pmid">20600251</pub-id></element-citation></ref><ref id="CR28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazekamp</surname><given-names>A</given-names></name><name><surname>Ruhaak</surname><given-names>R</given-names></name><name><surname>Zuurman</surname><given-names>L</given-names></name><name><surname>van Gerven</surname><given-names>J</given-names></name><name><surname>Verpoorte</surname><given-names>R</given-names></name></person-group><article-title>Evaluation of a vaporizing device (Volcano&#x000ae;) for the pulmonary administration of tetrahydrocannabinol</article-title><source>J Pharm Sci</source><year>2006</year><volume>95</volume><fpage>1308</fpage><lpage>1317</lpage><pub-id pub-id-type="doi">10.1002/jps.20574</pub-id><pub-id pub-id-type="pmid">16637053</pub-id></element-citation></ref><ref id="CR29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirvonen</surname><given-names>J</given-names></name><name><surname>Goodwin</surname><given-names>RS</given-names></name><name><surname>Li</surname><given-names>CT</given-names></name><name><surname>Terry</surname><given-names>GE</given-names></name><name><surname>Zoghbi</surname><given-names>SS</given-names></name><name><surname>Morse</surname><given-names>C</given-names></name><name><surname>Pike</surname><given-names>VW</given-names></name><name><surname>Volkow</surname><given-names>ND</given-names></name><name><surname>Huestis</surname><given-names>MA</given-names></name><name><surname>Innis</surname><given-names>RB</given-names></name></person-group><article-title>Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers</article-title><source>Mol Psychiatry</source><year>2012</year><volume>17</volume><fpage>642</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1038/mp.2011.82</pub-id><pub-id pub-id-type="pmid">21747398</pub-id></element-citation></ref><ref id="CR30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>AF</given-names></name><name><surname>Oz</surname><given-names>M</given-names></name><name><surname>Caulder</surname><given-names>T</given-names></name><name><surname>Lupica</surname><given-names>CR</given-names></name></person-group><article-title>Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure</article-title><source>J Neurosci</source><year>2003</year><volume>23</volume><fpage>4815</fpage><lpage>4820</lpage><pub-id pub-id-type="pmid">12832502</pub-id></element-citation></ref><ref id="CR31"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hommel</surname><given-names>B</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Todd</surname><given-names>PM</given-names></name><name><surname>Hills</surname><given-names>TT</given-names></name><name><surname>Robbins</surname><given-names>TW</given-names></name></person-group><article-title>Convergent and divergent operations in cognitive search</article-title><source>Cognitive search: evolution, algorithms, and the brain</source><year>2012</year><publisher-loc>Cambridge, MA</publisher-loc><publisher-name>MIT Press</publisher-name><fpage>221</fpage><lpage>235</lpage></element-citation></ref><ref id="CR32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzlicht</surname><given-names>M</given-names></name><name><surname>Schmeichel</surname><given-names>BJ</given-names></name></person-group><article-title>What is ego depletion? Toward a mechanistic revision of the resource model of self-control</article-title><source>Perspect Psychol Sci</source><year>2012</year><volume>7</volume><fpage>450</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1177/1745691612454134</pub-id></element-citation></ref><ref id="CR33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelleher</surname><given-names>LM</given-names></name><name><surname>Stough</surname><given-names>C</given-names></name><name><surname>Sergejew</surname><given-names>AA</given-names></name><name><surname>Rolfe</surname><given-names>T</given-names></name></person-group><article-title>The effects of cannabis on information-processing speed</article-title><source>Addict Behav</source><year>2004</year><volume>29</volume><fpage>1213</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2004.03.039</pub-id><pub-id pub-id-type="pmid">15236825</pub-id></element-citation></ref><ref id="CR34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuepper</surname><given-names>R</given-names></name><name><surname>Morrison</surname><given-names>PD</given-names></name><name><surname>van Os</surname><given-names>J</given-names></name><name><surname>Murray</surname><given-names>RM</given-names></name><name><surname>Kenis</surname><given-names>G</given-names></name><name><surname>Henquet</surname><given-names>C</given-names></name></person-group><article-title>Does dopamine mediate the psychosis-inducing effects of cannabis? A review and integration of findings across disciplines</article-title><source>Schizophr Res</source><year>2010</year><volume>121</volume><fpage>107</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.schres.2010.05.031</pub-id><pub-id pub-id-type="pmid">20580531</pub-id></element-citation></ref><ref id="CR35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuepper</surname><given-names>R</given-names></name><name><surname>Ceccarini</surname><given-names>J</given-names></name><name><surname>Lataster</surname><given-names>J</given-names></name><name><surname>van Os</surname><given-names>J</given-names></name><name><surname>van Kroonenburgh</surname><given-names>M</given-names></name><name><surname>van Gerven</surname><given-names>JM</given-names></name><name><surname>Marcelis</surname><given-names>M</given-names></name><name><surname>Van Laere</surname><given-names>K</given-names></name><name><surname>Henquet</surname><given-names>C</given-names></name></person-group><article-title>Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: <sup>18</sup>F-fallypride positron emission tomography study</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><fpage>e70378</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0070378</pub-id><pub-id pub-id-type="pmid">23936196</pub-id></element-citation></ref><ref id="CR36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecrubier</surname><given-names>Y</given-names></name><name><surname>Sheehan</surname><given-names>DV</given-names></name><name><surname>Weiller</surname><given-names>E</given-names></name><name><surname>Amorim</surname><given-names>P</given-names></name><name><surname>Bonora</surname><given-names>I</given-names></name><name><surname>Sheehan</surname><given-names>K</given-names></name><name><surname>Janavs</surname><given-names>J</given-names></name><name><surname>Dunbar</surname><given-names>G</given-names></name></person-group><article-title>The mini international neuropsychiatric interview (M.I.N.I.). A short diagnostic structured interview: reliability and validity according to the CIDI</article-title><source>Eur Psychiat</source><year>1997</year><volume>12</volume><fpage>224</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1016/S0924-9338(97)83296-8</pub-id></element-citation></ref><ref id="CR37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>J</given-names></name><name><surname>Schleifer</surname><given-names>L</given-names></name><name><surname>Richards</surname><given-names>JB</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>Effects of THC on behavioral measures of impulsivity in humans</article-title><source>Neuropsychopharmacology</source><year>2003</year><volume>28</volume><fpage>1356</fpage><lpage>1365</lpage><pub-id pub-id-type="doi">10.1038/sj.npp.1300176</pub-id><pub-id pub-id-type="pmid">12784123</pub-id></element-citation></ref><ref id="CR38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mednick</surname><given-names>S</given-names></name></person-group><article-title>The associative basis of creative problem solving process</article-title><source>Psychol Rev</source><year>1962</year><volume>69</volume><fpage>200</fpage><lpage>232</lpage></element-citation></ref><ref id="CR39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mink</surname><given-names>JW</given-names></name></person-group><article-title>The basal ganglia: focused selection and inhibition of competing motor programs</article-title><source>Prog Neurobiol</source><year>1996</year><volume>50</volume><fpage>381</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1016/S0301-0082(96)00042-1</pub-id><pub-id pub-id-type="pmid">9004351</pub-id></element-citation></ref><ref id="CR40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nijstad</surname><given-names>BA</given-names></name><name><surname>de Dreu</surname><given-names>CKW</given-names></name><name><surname>Rietzschel</surname><given-names>EF</given-names></name><name><surname>Baas</surname><given-names>M</given-names></name></person-group><article-title>The dual pathway to creativity model: creative ideation as a function of flexibility and persistence</article-title><source>Eur Rev Soc Psych</source><year>2010</year><volume>21</volume><fpage>34</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1080/10463281003765323</pub-id></element-citation></ref><ref id="CR41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaekers</surname><given-names>JG</given-names></name><name><surname>Kauert</surname><given-names>G</given-names></name><name><surname>van Ruitenbeek</surname><given-names>P</given-names></name><name><surname>Theunissen</surname><given-names>EL</given-names></name><name><surname>Schneider</surname><given-names>E</given-names></name><name><surname>Moeller</surname><given-names>MR</given-names></name></person-group><article-title>High-potency marijuana impairs executive function and inhibitory motor control</article-title><source>Neuropsychopharmacology</source><year>2006</year><volume>31</volume><fpage>2296</fpage><lpage>2303</lpage><pub-id pub-id-type="pmid">16572123</pub-id></element-citation></ref><ref id="CR42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaekers</surname><given-names>JG</given-names></name><name><surname>Kauert</surname><given-names>G</given-names></name><name><surname>Theunissen</surname><given-names>EL</given-names></name><name><surname>Toennes</surname><given-names>SW</given-names></name><name><surname>Moeller</surname><given-names>MR</given-names></name></person-group><article-title>Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users</article-title><source>J Psychopharmacol</source><year>2009</year><volume>23</volume><fpage>266</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1177/0269881108092393</pub-id><pub-id pub-id-type="pmid">18719045</pub-id></element-citation></ref><ref id="CR43"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Raven</surname><given-names>JC</given-names></name><name><surname>Court</surname><given-names>JH</given-names></name><name><surname>Raven</surname><given-names>J</given-names></name></person-group><source>Manual for Raven&#x02019;s progressive matrices and vocabulary scales</source><year>1988</year><publisher-loc>London</publisher-loc><publisher-name>Lewis</publisher-name></element-citation></ref><ref id="CR44"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Runco</surname><given-names>MA</given-names></name></person-group><source>Creativity: theories, themes, and issues</source><year>2007</year><publisher-loc>San Diego, CA</publisher-loc><publisher-name>Academic</publisher-name></element-citation></ref><ref id="CR45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>JA</given-names></name><name><surname>Weis</surname><given-names>A</given-names></name><name><surname>Mendelsohn</surname><given-names>GA</given-names></name></person-group><article-title>Affect grid: a single-item scale of pleasure and arousal</article-title><source>J Pers Soc Psychol</source><year>1989</year><volume>57</volume><fpage>493</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1037/0022-3514.57.3.493</pub-id></element-citation></ref><ref id="CR46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>EB</given-names></name></person-group><article-title>Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects</article-title><source>Br J Pharmacol</source><year>2011</year><volume>163</volume><fpage>1344</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1111/j.1476-5381.2011.01238.x</pub-id><pub-id pub-id-type="pmid">21749363</pub-id></element-citation></ref><ref id="CR47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schafer</surname><given-names>G</given-names></name><name><surname>Feilding</surname><given-names>A</given-names></name><name><surname>Morgan</surname><given-names>CJ</given-names></name><name><surname>Agathangelou</surname><given-names>M</given-names></name><name><surname>Freeman</surname><given-names>TP</given-names></name><name><surname>Curran</surname><given-names>HV</given-names></name></person-group><article-title>Investigating the interaction between schizotypy, divergent thinking and cannabis use</article-title><source>Conscious Cogn</source><year>2012</year><volume>21</volume><fpage>292</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.concog.2011.11.009</pub-id><pub-id pub-id-type="pmid">22230356</pub-id></element-citation></ref><ref id="CR48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>S</given-names></name><name><surname>Arning</surname><given-names>L</given-names></name><name><surname>Pinnow</surname><given-names>M</given-names></name><name><surname>Wascher</surname><given-names>E</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name><name><surname>Beste</surname><given-names>C</given-names></name></person-group><article-title>When control fails: influence of the prefrontal but not striatal dopaminergic system on behavioural flexibility in a change detection task</article-title><source>Neuropharmacology</source><year>2012</year><volume>62</volume><fpage>1028</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1016/j.neuropharm.2011.10.012</pub-id><pub-id pub-id-type="pmid">22067551</pub-id></element-citation></ref><ref id="CR49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>DJ</given-names></name><name><surname>Stohler</surname><given-names>CS</given-names></name><name><surname>Egnatuk</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Koeppe</surname><given-names>RA</given-names></name><name><surname>Zubieta</surname><given-names>JK</given-names></name></person-group><article-title>Individual differences in reward responding explain placebo-induced expectations and effects</article-title><source>Neuron</source><year>2007</year><volume>55</volume><fpage>325</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2007.06.028</pub-id><pub-id pub-id-type="pmid">17640532</pub-id></element-citation></ref><ref id="CR50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>DJ</given-names></name><name><surname>Stohler</surname><given-names>CS</given-names></name><name><surname>Egnatuk</surname><given-names>CM</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Koeppe</surname><given-names>RA</given-names></name><name><surname>Zubieta</surname><given-names>JK</given-names></name></person-group><article-title>Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses</article-title><source>Arch Gen Psychiatry</source><year>2008</year><volume>65</volume><fpage>220</fpage><lpage>231</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2007.34</pub-id><pub-id pub-id-type="pmid">18250260</pub-id></element-citation></ref><ref id="CR51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stadelman</surname><given-names>AM</given-names></name><name><surname>Juckel</surname><given-names>G</given-names></name><name><surname>Arning</surname><given-names>L</given-names></name><name><surname>Gallinat</surname><given-names>J</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name><name><surname>Roser</surname><given-names>P</given-names></name></person-group><article-title>Association between a cannabinoid receptor gene (CNR1) polymorphism and cannabinoid-induced alterations of the auditory event-related P300 potential</article-title><source>Neurosci Lett</source><year>2011</year><volume>496</volume><fpage>60</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.neulet.2011.04.003</pub-id><pub-id pub-id-type="pmid">21513772</pub-id></element-citation></ref><ref id="CR52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tart</surname><given-names>CT</given-names></name></person-group><article-title>Marijuana intoxication: common experiences</article-title><source>Nature</source><year>1970</year><volume>226</volume><fpage>701</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1038/226701a0</pub-id><pub-id pub-id-type="pmid">5443246</pub-id></element-citation></ref><ref id="CR53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theunissen</surname><given-names>EL</given-names></name><name><surname>Kauert</surname><given-names>GF</given-names></name><name><surname>Toennes</surname><given-names>SW</given-names></name><name><surname>Moeller</surname><given-names>MR</given-names></name><name><surname>Sambeth</surname><given-names>A</given-names></name><name><surname>Blanchard</surname><given-names>MM</given-names></name><name><surname>Ramaekers</surname><given-names>JG</given-names></name></person-group><article-title>Neurophysiological functioning of occasional and heavy cannabis users during THC intoxication</article-title><source>Psychopharmacology (Berl)</source><year>2012</year><volume>220</volume><fpage>341</fpage><lpage>350</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2479-x</pub-id><pub-id pub-id-type="pmid">21975580</pub-id></element-citation></ref><ref id="CR54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tinklenberg</surname><given-names>JR</given-names></name><name><surname>Darley</surname><given-names>CF</given-names></name><name><surname>Roth</surname><given-names>WT</given-names></name><name><surname>Pfefferbaum</surname><given-names>A</given-names></name><name><surname>Kopell</surname><given-names>BS</given-names></name></person-group><article-title>Marijuana effects on associations to novel stimuli</article-title><source>J Nerv Ment Dis</source><year>1978</year><volume>166</volume><fpage>362</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1097/00005053-197805000-00008</pub-id><pub-id pub-id-type="pmid">650201</pub-id></element-citation></ref><ref id="CR55"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Torrance</surname><given-names>EP</given-names></name></person-group><source>Torrance tests of creative thinking-norms</source><year>1966</year><publisher-loc>Lexington, MA</publisher-loc><publisher-name>Personal Press</publisher-name></element-citation></ref><ref id="CR56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Urban</surname><given-names>NB</given-names></name><name><surname>Slifstein</surname><given-names>M</given-names></name><name><surname>Thompson</surname><given-names>JL</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Girgis</surname><given-names>RR</given-names></name><name><surname>Raheja</surname><given-names>S</given-names></name><name><surname>Haney</surname><given-names>M</given-names></name><name><surname>Abi-Dargham</surname><given-names>A</given-names></name></person-group><article-title>Dopamine release in chronic cannabis users: a [<sup>11</sup>c]raclopride positron emission tomography study</article-title><source>Biol Psychiatry</source><year>2012</year><volume>71</volume><fpage>677</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2011.12.018</pub-id><pub-id pub-id-type="pmid">22290115</pub-id></element-citation></ref><ref id="CR57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weckowicz</surname><given-names>TE</given-names></name><name><surname>Fedora</surname><given-names>O</given-names></name><name><surname>Mason</surname><given-names>J</given-names></name><name><surname>Radstaak</surname><given-names>D</given-names></name><name><surname>Bay</surname><given-names>KS</given-names></name><name><surname>Yonge</surname><given-names>KA</given-names></name></person-group><article-title>Effect of marijuana on divergent and convergent production cognitive tests</article-title><source>J Abnorm Psychol</source><year>1975</year><volume>84</volume><fpage>386</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1037/0021-843X.84.4.386</pub-id><pub-id pub-id-type="pmid">1100706</pub-id></element-citation></ref><ref id="CR58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zenasni</surname><given-names>F</given-names></name><name><surname>Lubart</surname><given-names>T</given-names></name></person-group><article-title>Pleasantness of creative tasks and creative performance</article-title><source>Think Skills and Creat</source><year>2011</year><volume>6</volume><fpage>49</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1016/j.tsc.2010.10.005</pub-id></element-citation></ref><ref id="CR59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zuurman</surname><given-names>L</given-names></name><name><surname>Roy</surname><given-names>C</given-names></name><name><surname>Schoemaker</surname><given-names>RC</given-names></name><name><surname>Hazekamp</surname><given-names>A</given-names></name><name><surname>den Hartigh</surname><given-names>J</given-names></name><name><surname>Bender</surname><given-names>JC</given-names></name><name><surname>Verpoorte</surname><given-names>R</given-names></name><name><surname>Pinquier</surname><given-names>JL</given-names></name><name><surname>Cohen</surname><given-names>AF</given-names></name><name><surname>van Gerven</surname><given-names>JM</given-names></name></person-group><article-title>Effect of intrapulmonary tetrahydrocannabinol administration in humans</article-title><source>J Psychopharmacol</source><year>2008</year><volume>22</volume><fpage>707</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1177/0269881108089581</pub-id><pub-id pub-id-type="pmid">18515447</pub-id></element-citation></ref></ref-list></back></article>